DK1817079T3 - Behandling af inflammationer - Google Patents

Behandling af inflammationer

Info

Publication number
DK1817079T3
DK1817079T3 DK05813139T DK05813139T DK1817079T3 DK 1817079 T3 DK1817079 T3 DK 1817079T3 DK 05813139 T DK05813139 T DK 05813139T DK 05813139 T DK05813139 T DK 05813139T DK 1817079 T3 DK1817079 T3 DK 1817079T3
Authority
DK
Denmark
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
DK05813139T
Other languages
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1817079(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DK1817079T3 publication Critical patent/DK1817079T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK05813139T 2004-12-02 2005-11-30 Behandling af inflammationer DK1817079T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001280 WO2006059328A1 (en) 2004-12-02 2005-11-30 Treatment of inflammation

Publications (1)

Publication Number Publication Date
DK1817079T3 true DK1817079T3 (da) 2008-11-17

Family

ID=35708899

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05813139T DK1817079T3 (da) 2004-12-02 2005-11-30 Behandling af inflammationer

Country Status (13)

Country Link
US (3) US20080056992A1 (da)
EP (2) EP1817589B1 (da)
JP (2) JP4842964B2 (da)
KR (2) KR20070100261A (da)
AT (2) ATE434762T1 (da)
AU (2) AU2005310874B2 (da)
BR (2) BRPI0518795A2 (da)
CA (2) CA2586774A1 (da)
DE (2) DE602005008639D1 (da)
DK (1) DK1817079T3 (da)
ES (2) ES2309817T3 (da)
MX (2) MX2007006500A (da)
WO (2) WO2006059328A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (en) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Treatment and monitoring disease state of liver cancer
EP1959939B1 (en) * 2005-11-30 2012-01-11 Can-Fite Biopharma Ltd. Use of a3 adenosine receptor agonist in osteoarthritis treatment
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2008056361A1 (en) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. A biological marker for psoriasis
HUE034474T2 (en) 2007-03-14 2018-02-28 Can Fite Biopharma Ltd Method for the synthesis of IB-meca
IL200753A (en) * 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20130045943A1 (en) * 2010-03-03 2013-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of A3ar agonists for the treatment of uveitis
WO2011158904A1 (ja) * 2010-06-18 2011-12-22 株式会社林原生物化学研究所 アデノシンｎ１－オキシドを有効成分として含有する炎症性疾患治療剤
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985005031A1 (en) 1984-05-09 1985-11-21 The Australian National University A method for the modulation of the immune response
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
WO1998024463A2 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using a tnf binding protein for treating tnf-mediated diseases
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
EP1554574A2 (en) * 2002-10-21 2005-07-20 Can-Fite Biopharma Ltd. Diagnostic markers for therapeutic treatment
JP2006503574A (ja) * 2002-10-22 2006-02-02 カン−フィテ・バイオファーマ・リミテッド 疾患の状態に関するマーカーとしてのａ３ａｒ
WO2004045627A1 (en) * 2002-11-19 2004-06-03 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
US7605166B2 (en) 2003-06-25 2009-10-20 Elan Pharmaceuticals Inc. Methods and compositions for treating rheumatoid arthritis
JP2007517019A (ja) 2003-12-29 2007-06-28 カン−フィテ・バイオファーマ・リミテッド 多発性硬化症の治療方法

Also Published As

Publication number Publication date
DE602005008639D1 (de) 2008-09-11
ATE434762T1 (de) 2009-07-15
US8541182B2 (en) 2013-09-24
AU2005310874B2 (en) 2008-11-27
ES2327435T3 (es) 2009-10-29
JP2008522182A (ja) 2008-06-26
WO2006059327A1 (en) 2006-06-08
JP4842964B2 (ja) 2011-12-21
US20100256084A1 (en) 2010-10-07
BRPI0518795A2 (pt) 2008-12-09
MX2007006501A (es) 2007-07-13
ATE402739T1 (de) 2008-08-15
US20080056992A1 (en) 2008-03-06
AU2005310874A1 (en) 2006-06-08
EP1817079B1 (en) 2008-07-30
BRPI0518777A2 (pt) 2008-12-09
WO2006059328A1 (en) 2006-06-08
CA2586774A1 (en) 2006-06-08
AU2005310873B2 (en) 2008-11-27
EP1817589A1 (en) 2007-08-15
ES2309817T3 (es) 2008-12-16
KR20070100261A (ko) 2007-10-10
DE602005015135D1 (de) 2009-08-06
EP1817079A1 (en) 2007-08-15
EP1817589B1 (en) 2009-06-24
KR20070090222A (ko) 2007-09-05
JP2008521883A (ja) 2008-06-26
AU2005310873A1 (en) 2006-06-08
MX2007006500A (es) 2007-07-13
CA2586773C (en) 2018-03-27
US20130345163A1 (en) 2013-12-26
CA2586773A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
EA201201199A1 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
DK2848938T3 (da) Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
WO2007123976A3 (en) Antibody profiling for determination of patient responsiveness
DK1817079T3 (da) Behandling af inflammationer
BRPI0415180A (pt) bateria
NZ610356A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
EA200870410A1 (ru) Антагонисты киназы
PT1701150T (pt) Contagem de glóbulos brancos
MX349225B (es) Uso de celulas madre placentarias para preparar medicamentos utiles en el tratamiento de padecimientos inflamatorios.
IT1394617B1 (it) Metodi integrati per la determinazione della corrosivita', dell'invecchiamento, del fingerprint, nonchè la diagnosi, la decontaminazione, la depolarizzazione e la detossificazione di oli
BR112012025517A2 (pt) ____________________________________________________________ anticorpo que reconhece fator inibidor de leucemia (lif) humano e uso de anti-lif anticorpos no tratamento de doenças associadas a proliferação celular não desejada
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
AR099856A1 (es) Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
PL2129391T3 (pl) Metoda diagnostyczna
DE602007006672D1 (de) Testverfahren und kit zur vorhersage des implantationserfolgs bei unterstützter befruchtung
EP2300599A4 (en) INCREASING THE EFFECTIVENESS OF CELL THERAPY, INCLUDING TREATMENT WITH ALPHA-1-3-FUCOSYLTRANSFERASE
EP1828284A4 (en) SULPONATED MULTIBLOCK COPOLYMER AND ELECTROLYTE MEMBRANE THEREWITH
ATE482393T1 (de) Diagnose und überwachung von entzündlichen krankheiten mittels messung der zusätzlichen komponenten von leukozyten
DK2068938T3 (da) Optimering af behandlingen af Philadelphia-positiv leukæmi med ABL-tyrosinkinaseinhibitor imatinib
EA201500526A1 (ru) Композиции и методы лечения воспалительных заболеваний инфекционного и неинфекционного происхождения
Weger et al. The methylenetetrahydrofolate reductase 677C> T gene polymorphism is not associated with chronic plaque psoriasis
WO2007044622A8 (en) Use of mif and mif pathway agonists
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
NZ599373A (en) Biomarkers for predicting rapid response to hcv treatment